Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains.
about
Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules.Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.HIV-1 protease dimer interface mutations that compensate for viral reverse transcriptase instability in infectious virions.Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates.Mutation rates and intrinsic fidelity of retroviral reverse transcriptases.Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.Altered error specificity of RNase H-deficient HIV-1 reverse transcriptases during DNA-dependent DNA synthesis.Stabilization of human immunodeficiency virus type 1 reverse transcriptase by site-directed mutagenesis.Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapyThermostable HIV-1 group O reverse transcriptase variants with the same fidelity as murine leukaemia virus reverse transcriptase.The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
P2860
Q34120878-EEB155E3-5C3A-4515-99DB-FBD050392466Q34976859-4A4EA801-05BB-4508-A6E9-DB781A422CA5Q35842525-F557E023-C950-4315-80D4-837B9758630BQ37227218-BDC5AA15-FFC5-48B9-8A9B-F127B6CD65FFQ37432131-7BEAD56C-7CA1-403B-8CF4-7CCD1B1ED0FBQ37568313-839A7C38-A44C-4D8B-A79A-7E645CDDB7DCQ37945186-0F396E8C-96AF-4AA9-8748-6F83FA643D22Q39664167-D9E59CC2-15DA-4A6C-9FA7-A1C55086E13DQ39986756-9CFC64CB-0455-4EFB-A89F-E950BE15909DQ42265862-08A4EDCD-CDBB-4043-B67A-8F534A8BDDE3Q42430831-A41D986A-17DC-4FAE-B00E-266761D5937FQ45367817-C188F93F-D26E-4D1B-A1FB-2FEB1334DC44Q45475260-E7DE06C9-5B2D-435C-86E3-A43412CED27DQ54567693-13987672-A774-4E9F-8FF8-D2D1B55029C7
P2860
Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Functional characterization of ...... t HIV-1 group M and O strains.
@en
Functional characterization of ...... t HIV-1 group M and O strains.
@nl
type
label
Functional characterization of ...... t HIV-1 group M and O strains.
@en
Functional characterization of ...... t HIV-1 group M and O strains.
@nl
prefLabel
Functional characterization of ...... t HIV-1 group M and O strains.
@en
Functional characterization of ...... t HIV-1 group M and O strains.
@nl
P2093
P2860
P50
P356
P1476
Functional characterization of ...... nt HIV-1 group M and O strains
@en
P2093
Quiñones-Mateu ME
P2860
P304
27470-27479
P356
10.1074/JBC.M104342200
P407
P577
2001-05-15T00:00:00Z